健康元(600380.SH)子公司“ω-3魚油中/長鏈脂肪乳注射液“獲藥品註冊證書
格隆匯12月16日丨健康元(600380.SH)公佈,近日,公司全資子公司深圳市海濱製藥有限公司(以下簡稱:深圳海濱)收到國家藥品監督管理局核准簽發的《藥品註冊證書》。
“ω-3魚油中/長鏈脂肪乳注射液“為公司與中國科學院上海藥物研究所合作開發的產品。與傳統的中/長鏈脂肪乳相比較,本品中增加了ω-3脂肪酸甘油三酯成分,其中富含EPA和DHA,可降低使用大豆油引起的炎症反應,縮短患者的住院時間。此外,本品的中鏈甘油三酸酯、大豆油及ω-3酸甘油三酯處方比例具有優化水解的作用,水解速率快,毒副反應少。截止本公告日,公司累計直接投入ω-3魚油中/長鏈脂肪乳注射液的研發費用約人民幣3493.56萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.